These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 9148185)
1. [Report on satellite symposium on interferon beta therapy in multiple sclerosis, Newcastle on Tyne (England), June 26, 1996]. Cendrowski W Neurol Neurochir Pol; 1996; 30(5):879-80. PubMed ID: 9148185 [No Abstract] [Full Text] [Related]
2. [Comments on satellite symposium on the treatment of patients with multiple sclerosis with interferon-beta-1b, Munich (Germany), June 19, 1995]. Cendrowski W Neurol Neurochir Pol; 1995; 29(6):979-80. PubMed ID: 8714735 [No Abstract] [Full Text] [Related]
3. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746 [TBL] [Abstract][Full Text] [Related]
4. [Report from the Satellite Symposium: Leading the way: outstanding efficacy of interferon beta-1b right from the start. Berlin, Germany, 06.24.2002]. Cendrowski W Neurol Neurochir Pol; 2002; 36(6):1260-3. PubMed ID: 12715704 [No Abstract] [Full Text] [Related]
5. [Satellite decade symposium of achievements and the future of multiple sclerosis treatment. 19. Congress ECTRIMS, Mediolan (Italy), September 19, 2003]. Cendrowski W Neurol Neurochir Pol; 2004; 38(1):73-4. PubMed ID: 15049175 [No Abstract] [Full Text] [Related]
6. 'Time is brain' also in multiple sclerosis. Freedman MS Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740 [No Abstract] [Full Text] [Related]
7. The curious incident of disability in multiple sclerosis trials. Coles A Lancet Neurol; 2006 Nov; 5(11):899-900. PubMed ID: 17052654 [No Abstract] [Full Text] [Related]
8. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis. Duddy M; Palace J Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247 [No Abstract] [Full Text] [Related]
9. [A short history of beta-interferon therapy of multiple sclerosis]. Stock G; Horowski R Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113 [TBL] [Abstract][Full Text] [Related]
14. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta. McDonald WI; Miller DH; Thompson AJ Ann Neurol; 1994 Jul; 36(1):14-8. PubMed ID: 8024255 [No Abstract] [Full Text] [Related]
16. Sjögren's syndrome with central nervous system involvement presenting as multiple sclerosis with failure response to beta-interferon. Tsai KY; Tsai CP; Liao N Eur Neurol; 2001; 45(1):59-60. PubMed ID: 11150847 [No Abstract] [Full Text] [Related]